Observed Signal · Aug 6, 2026 · Partnership · Source: Adweek · Impact: 3/5 · Sentiment: Positive

Agency & Consultancy Market: Omnicom Wins U.S. Media Account for Novo Nordisk

Executive Signal Summary

Omnicom has been named agency-of-record to handle Novo Nordisk’s U.S. media planning and buying, winning the business from incumbent WPP. The U.S. portion of the account is valued at $520 million, while the global account is valued at $618 million, according to COMvergence. Novo Nordisk, the Danish pharmaceutical company behind GLP-1 drugs Ozempic and Wegovy, said it will work with Omnicom to scale consumer-focused strategies and connect with patients through emerging channels and technologies. The account win was reported by Adweek on 2026-08-06.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

Large U.S. media account ($520M) and global spend ($618M) moving to Omnicom from incumbent WPP matters to agency competition and media-buying market dynamics.

Key Takeaways & Evidence Grounding

  • Omnicom will be the agency-of-record to manage Novo Nordisk’s U.S. media planning and buying.
  • Omnicom beat incumbent WPP for the U.S. media account.
  • The U.S. account is valued at $520 million; the global account is valued at $618 million, per COMvergence.
  • Novo Nordisk manufactures GLP-1 medications Ozempic and Wegovy.
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: AdweekPublished: Aug 6, 2026
Original Coverage Title: Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk

Track Real-Time Market Signals & Shifts

Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.